O

nce again, Brent Saunders is standing out from the pharma c-suite crowd.

Over the weekend, the Allergan chief executive was the only head of a major drug maker to publicly say anything about the highly controversial Trump immigration ban. And what Saunders had to say was not supportive, at all, of the move: Allergan, he tweeted, “is strong & bold b/c of diversity. Oppose any policy that puts limitations on our ability to attract the best & diverse talent.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories